GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qurient Co Ltd (XKRX:115180) » Definitions » EV-to-FCF

Qurient Co (XKRX:115180) EV-to-FCF : -4.13 (As of Sep. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Qurient Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Qurient Co's Enterprise Value is ₩84,038 Mil. Qurient Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-20,369 Mil. Therefore, Qurient Co's EV-to-FCF for today is -4.13.

The historical rank and industry rank for Qurient Co's EV-to-FCF or its related term are showing as below:

XKRX:115180' s EV-to-FCF Range Over the Past 10 Years
Min: -13.98   Med: -4.14   Max: -1.58
Current: -4.69

During the past 10 years, the highest EV-to-FCF of Qurient Co was -1.58. The lowest was -13.98. And the median was -4.14.

XKRX:115180's EV-to-FCF is ranked worse than
100% of 400 companies
in the Biotechnology industry
Industry Median: 6.825 vs XKRX:115180: -4.69

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-09-27), Qurient Co's stock price is ₩4280.00. Qurient Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-820.351. Therefore, Qurient Co's PE Ratio (TTM) for today is At Loss.


Qurient Co EV-to-FCF Historical Data

The historical data trend for Qurient Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qurient Co EV-to-FCF Chart

Qurient Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.20 -12.15 -9.02 -3.98 -3.88

Qurient Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.81 -2.64 -3.88 -4.49 -3.20

Competitive Comparison of Qurient Co's EV-to-FCF

For the Biotechnology subindustry, Qurient Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qurient Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qurient Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Qurient Co's EV-to-FCF falls into.



Qurient Co EV-to-FCF Calculation

Qurient Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=84038.248/-20368.844
=-4.13

Qurient Co's current Enterprise Value is ₩84,038 Mil.
Qurient Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-20,369 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qurient Co  (XKRX:115180) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Qurient Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4280.00/-820.351
=At Loss

Qurient Co's share price for today is ₩4280.00.
Qurient Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-820.351.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Qurient Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Qurient Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Qurient Co Business Description

Traded in Other Exchanges
N/A
Address
C-dong 8th Floor, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, KOR, 13487
Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.

Qurient Co Headlines

No Headlines